Description:
In the dose escalation phase (Part 1), this study will determine the dose-limiting toxicities
(DLTs), the maximum tolerated dose (MTD) and recommended Phase 2 (RPII) dose of NC 6004 in
combination with gemcitabine.
In the expansion phase of the study (Part 2), study will evaluate the activity, safety, and
tolerability at the RPII dose identified in Part 1 in patients with squamous NSCLC, biliary
tract, and bladder cancer.
Title
- Brief Title: Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer
- Official Title: A Phase 1b/2 Dose Escalation and Expansion Trial of NC-6004 (Nanoparticle Cisplatin) Plus Gemcitabine in Patients With Advanced Solid Tumors or Non-Small Cell Lung, Biliary Tract, and Bladder Cancer
Clinical Trial IDs
- ORG STUDY ID:
NC-6004-004A
- NCT ID:
NCT02240238
Conditions
Interventions
Drug | Synonyms | Arms |
---|
NC-6004 | | NC-6004 and Gemcitabine |
Gemcitabine | | NC-6004 and Gemcitabine |
Purpose
In the dose escalation phase (Part 1), this study will determine the dose-limiting toxicities
(DLTs), the maximum tolerated dose (MTD) and recommended Phase 2 (RPII) dose of NC 6004 in
combination with gemcitabine.
In the expansion phase of the study (Part 2), study will evaluate the activity, safety, and
tolerability at the RPII dose identified in Part 1 in patients with squamous NSCLC, biliary
tract, and bladder cancer.
Trial Arms
Name | Type | Description | Interventions |
---|
NC-6004 and Gemcitabine | Experimental | | |
Eligibility Criteria
Inclusion Criteria:
- (Part 1 only) Have a histologically or cytologically confirmed diagnosis of advanced
solid tumor that has relapsed or is refractory to standard curative or palliative
therapy or has a contraindication to standard therapy.
- (Part 2 only) Cohort 1: Have histologically or cytologically confirmed diagnosis of
Stage IV squamous NSCLC and have not received prior chemotherapy or immunotherapy for
metastatic disease and are not known to be PD-L1 positive (known high PD-L1 expression
defined as Tumor Proportion Score [TPS] greater than or equal to 50%). Patients with
known sensitizing mutation in the epidermal growth factor receptor (EGFR) gene or
anaplastic lymphoma kinase (ALK) fusion oncogene must have received at least 1 and up
to 2 targeted therapies prior to enrollment.
- (Part 2 only) Cohort 2: Have histologically or cytologically confirmed diagnosis of
nonresectable, recurrent, or metastatic biliary tract carcinoma (intrahepatic or
extrahepatic cholangiocarcinoma, gallbladder cancer, or ampullary carcinoma) and have
not received prior systemic anticancer therapy for advanced or metastatic disease.
- (Part 2 only) Cohort 3: Have histologically or cytologically confirmed diagnosis of
metastatic or locally advanced TCC of the urinary tract (bladder, urethra, ureter,
renal pelvis) (T3b-T4 N0 M0, Tany N1-N3 M0, or Tany Nany M1) and are not candidates
for surgery.
- Have measurable disease per RECIST version 1.1.
- Have an ECOG PS of 0 to 1, with the exception of patients in Part 2 (Cohort 3, unfit
bladder cancer patients) who may have an ECOG PS of 2
- Adequate bone marrow reserve, liver and renal function
- Have a negative pregnancy test result at Screening for females of childbearing
potential
- Male patients must agree to use a condom during treatment and for 90 days after dosing
and must agree not to donate sperm for 90 days after dosing
- Women of childbearing potential are willing to agree to use 1 of the study defined
effective methods of birth control from the time of study entry to 6 months after the
last day of treatment
- Reasonably recovered from preceding major surgery as judged by the investigator or no
major surgery within 4 weeks prior to the start of Day 1 treatment
Exclusion Criteria:
- Have received prior platinum therapy in the past 3 months (Part 1) or 6 months in the
adjuvant or neoadjuvant setting (Part 2).
- Have received prior cisplatin and gemcitabine concomitantly within the last 6 months
or are refractory to cisplatin and gemcitabine.
- Unresolved toxicity from prior radiation, chemotherapy, or other targeted treatment,
including investigational treatment
- Have evidence suggesting pulmonary fibrosis or interstitial pneumonia.
- Have a history of thrombocytopenia with complications
- Have known hypersensitivity to platinum compounds or gemcitabine.
- Have uncontrolled diabetes or have hypertension requiring more than 3 medications for
control of hypertension.
- Have pre-existing alcoholic liver injury or significant liver disease.
- Pregnant or breast feeding
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Determine the RPII dose of NC-6004 in combination with gemcitabine |
Time Frame: | 1 year |
Safety Issue: | |
Description: | In the dose-escalation phase of the study (Part 1), to determine the dose-limiting toxicities (DLTs), MTD, and RPII dose of NC-6004 in combination with gemcitabine |
Secondary Outcome Measures
Measure: | Overall response rate |
Time Frame: | every 6 weeks tumor assessments for response and disease progression after treatment discontinuation and telephone calls for survival every 12 weeks until disease progression. |
Safety Issue: | |
Description: | To evaluate ORR, DCR (DCR = complete response [CR] + partial response [PR] + stable disease [SD]), DOR, PFS, and OS |
Measure: | Therapy-related AEs |
Time Frame: | 1 year |
Safety Issue: | |
Description: | Incidence and severity of therapy-related AEs |
Measure: | EORTC QLQ-C30 |
Time Frame: | 1 year |
Safety Issue: | |
Description: | To evaluate QoL using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) |
Measure: | Safety and tolerability as measured by severity of AEs and laboratory abnormalities |
Time Frame: | 1 year |
Safety Issue: | |
Description: | The safety endpoints for this study are the incidence and severity of AEs and laboratory abnormalities, according to the NCI CTCAE version 4.03, the occurrence of SAEs and treatment discontinuations due to AEs, and nausea severity and vomiting incidence obtained from the patient diary |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Completed |
Lead Sponsor: | NanoCarrier Co., Ltd. |
Last Updated
February 28, 2020